TSE:4576'
s Quick Ratio Range Over the Past 10 Years
Min: 6.35 Med: 10.65 Max: 76.51
Current: 10.38
During the past 13 years, D. Western Therapeutics Institute's highest Quick Ratio was 76.51. The lowest was 6.35. And the median was 10.65.
TSE:4576's Quick Ratio is ranked better than 79.67% of 1412
companies
in the Biotechnology industry
Industry Median: 3.6
vs TSE:4576: 10.38
D. Western Therapeutics Institute (TSE:4576) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
D. Western Therapeutics Institute Quick Ratio Related Terms
D. Western Therapeutics Institute Quick Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
D. Western Therapeutics Institute Quick Ratio Chart
TSE:4576 vs VRTX, REGN, ALNY: Quick Ratio Comparison
For the Biotechnology subindustry, D. Western Therapeutics Institute's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
D. Western Therapeutics Institute Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, D. Western Therapeutics Institute's Quick Ratio distribution charts can be found below:
* The bar in red indicates where D. Western Therapeutics Institute's Quick Ratio falls into.
D. Western Therapeutics Institute Quick Ratio Calculation
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
D. Western Therapeutics Institute (TSE:4576) has a Quick Ratio of 9.48 as of Dec. 2025. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on D. Western Therapeutics Institute and its competitors. This is 11% below median its historical median of 10.65. Over the past decade, D. Western Therapeutics Institute's Quick Ratio has ranged from 6.35 to 76.51. According to the industry distribution chart, D. Western Therapeutics Institute ranks #287 out of 1412 companies in the Biotechnology industry, placing it in the top 20.3%.
Is D. Western Therapeutics Institute's Quick Ratio too high?
D. Western Therapeutics Institute's current Quick Ratio of 9.48 is 11% below median its 10-year median of 10.65. Over the past 10 years, this metric has ranged from a low of 6.35 to a high of 76.51. The Biotechnology industry median Quick Ratio is 3.60. D. Western Therapeutics Institute's value of 9.48 is 163.3% above this industry median. Based on the distribution chart, D. Western Therapeutics Institute ranks #287 out of 1412 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, D. Western Therapeutics Institute has a GF Score™ of 45/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does D. Western Therapeutics Institute's Quick Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, D. Western Therapeutics Institute ranks #287 out of 1412 companies for Quick Ratio. This places D. Western Therapeutics Institute in the top 20% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. D. Western Therapeutics Institute's value of 9.48 is 163.3% above this benchmark. Historically, D. Western Therapeutics Institute's own Quick Ratio has ranged from 6.35 to 76.51 over the past decade. While the company's 10-year median is 10.65 vs. the industry median of 3.60, D. Western Therapeutics Institute has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,412 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. D. Western Therapeutics Institute's current Quick Ratio of 9.48 is 163.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on D. Western Therapeutics Institute and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. D. Western Therapeutics Institute's current Quick Ratio is 9.48, which is 11% below median its own 10-year median of 10.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is D. Western Therapeutics Institute stock overvalued right now?
Based on GuruFocus' analysis, D. Western Therapeutics Institute (TSE:4576) is currently considered Modestly Overvalued. The stock's GF Value™ is 円64.35, compared to a current price of 円74.00 — trading 15% above its estimated fair value. The current Quick Ratio is 9.48, which is 11% below median its 10-year median of 10.65 and 163.3% above the Biotechnology industry median of 3.60. D. Western Therapeutics Institute's overall GF Score™ is 45/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For D. Western Therapeutics Institute (TSE:4576), the current Quick Ratio is 9.48 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is D. Western Therapeutics Institute (TSE:4576) Overvalued in 2026?
Based on GuruFocus' analysis, D. Western Therapeutics Institute stock appears to be overvalued.
The current stock price of 円74.00 is trading 15% above its estimated GF Value™ of 円64.35.
GuruFocus considers D. Western Therapeutics Institute to be Modestly Overvalued.
Key valuation signals for TSE:4576:
Quick Ratio: 9.48 (11% below median its 10-year median of 10.65)
GF Value™: 円64.35 vs. price of 円74.00 (15% above fair value)
Industry Position: 163.3% above the Biotechnology median (#287 of 1412)
No single metric tells the full story. See the TSE:4576 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
D. Western Therapeutics Institute Business Description
D. Western Therapeutics Institute Inc is engaged in the research and development of pharmaceutical drugs in Japan. Its products include ophthalmic solution and agents for antiplatelet and anti-glaucoma.
45GF Score
Get the complete analysis for TSE:4576
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:4576 has been successfully added to your 
